Using an HSA for PRP and Stem Cell Therapy: The Opportunity and the Trap

You asked about platelet-rich plasma. About bone marrow concentrate. About real regenerative treatment for a chronic, degenerative problem. And your insurance company gave you the answer it always gives: experimental, investigational, denied.

What that denial does not tell you is that the federal government applies a completely different standard — and that a Health Savings Account is governed by the federal standard, not by your carrier’s coverage policy.

This article explains both halves of that: the opportunity, and the compliance trap most regenerative clinics ignore entirely.

A necessary framing before anything else: this is educational information, not medical, tax, legal, or financial advice. HSA eligibility depends on your individual medical circumstances, documentation, and tax situation. Rules change. Confirm your own eligibility with your plan administrator and a qualified tax or financial professional before spending HSA funds on anything.

Two different questions being confused for one

When your insurer denies PRP as investigational, it is answering a narrow question: will this carrier pay for this? That determination is made by a commercial entity applying its own coverage criteria.

The HSA question is a different one entirely: does this expense qualify as a medical expense under federal tax law?

Under IRS Code Section 213(d), a Health Savings Account can be used to pay for treatments that diagnose, cure, mitigate, or treat a real disease or structural defect. The IRS does not tie that eligibility to what your insurance company approves. The two determinations are made by different bodies under different rules, and one does not govern the other.

If you are treating a genuine degenerative condition — osteoarthritis, severe tendinopathy — orthobiologic treatment can qualify as a medical expense paid with 100 percent pre-tax dollars.

That is a substantial difference in the real cost of care, and most patients never learn it exists because the denial letter reads like a verdict rather than one company’s coverage decision.

The compliance trap

Here is the part that gets skipped, and it is the part that carries real financial risk.

The eligibility above depends on the treatment being what it claims to be, delivered lawfully. Some clinics use non-compliant allogeneic products — biological material sourced from a donor rather than from you — that do not meet the requirements of 21 CFR Part 1271, the federal regulation governing human cells and tissue products.

When the product itself is non-compliant, the expense can be disqualified.

The consequence is not a letter asking you to try again. In an IRS audit, disqualified HSA spending can be reclassified as income — meaning you owe ordinary income tax on money you had treated as pre-tax — plus a 20 percent penalty.

Read that sequence carefully, because of who absorbs it. The clinic sourced the product. The clinic made the regulatory decision. The patient carries the tax exposure. You can do everything right on your end and still be exposed by a purchasing decision you were never told about.

Why autologous matters here

This is why the sourcing question is not a technicality.

Autologous orthobiologics are derived from your own body — your blood for PRP, your own marrow for bone marrow concentrate. Using autologous material eliminates the FDA compliance risk that attaches to non-compliant allogeneic products.

It is worth separating two reasons to care about that. The clinical reasons for autologous material are their own conversation. The point here is narrower and financial: the regulatory status of what is injected determines whether your pre-tax dollars were legitimately spent.

If you are considering paying for regenerative treatment with HSA funds anywhere, the question to ask the clinic is direct: is the product autologous, and if not, what is its regulatory status under 21 CFR Part 1271? A practice that cannot answer that clearly is a practice you are underwriting.

The audit trail: documentation is the protection

Eligibility is not established by belief. It is established by records.

The instrument that does this work is a formal Letter of Medical Necessity — physician documentation tying the treatment to the diagnosis of a real disease or structural defect, which is precisely the standard Section 213(d) describes.

The distinction is between an expense that was qualified and an expense you can demonstrate was qualified, years later, to someone who was not in the room. Those are not the same thing, and only the second one survives an audit.

The part that determines whether any of it was worth paying for

None of the above says anything about whether the treatment will work.

An orthobiologic procedure is an instruction to repair, and it is delivered into an environment. Treating the underlying terrain — metabolism, nutrition, inflammation — is what makes the therapy actually work. A perfectly documented, perfectly compliant, perfectly funded injection into a body that cannot execute the instruction is still a poor use of your money.

Which is the honest order of operations: first determine whether you are a clinical candidate, then determine how to pay for it. At Regen.MD the entry point is a $400 Clinical Evaluation, and whether any orthobiologic therapy is appropriate for you is decided there, not by a payment method.

Regen.MD is located at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport, serving the St. Louis metro including St. Louis County, St. Charles, Clayton, and Florissant.

Frequently asked questions

Key takeaways

• Your insurer’s “experimental” determination and the IRS definition of a qualified medical expense are separate standards applied by separate bodies.
• Under IRS Code Section 213(d), HSA funds can pay for treatment of a real disease or structural defect, potentially with 100 percent pre-tax dollars.
• Clinics using non-compliant allogeneic products under 21 CFR Part 1271 can cause your expense to be disqualified.
• A disqualified expense can be reclassified as income in an audit, plus a 20 percent penalty — the patient carries the exposure for the clinic’s sourcing decision.
• Autologous orthobiologics eliminate the FDA compliance risk, and a formal Letter of Medical Necessity is what makes eligibility demonstrable rather than merely asserted.

Medically reviewed by Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

This article is educational and is not medical, tax, legal, or financial advice, and is not a substitute for evaluation, diagnosis, or treatment by a physician. HSA eligibility depends on your individual medical circumstances, documentation, and tax situation; rules change, and references to IRS code and federal regulations are general in nature and should be independently verified with your plan administrator and a qualified tax or financial professional. Individual results vary, and not every patient is a candidate for the therapies described. Do not start, stop, or change any treatment without consulting your physician. Orthobiologic therapies including platelet-rich plasma and bone marrow concentrate are not FDA-approved for these indications and are provided as part of physician-directed care.